



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698

Date: June 30, 2025

To

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001.	National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai – 400051.
Scrip Code: 532989	Scrip Code: BAFNAPH

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of Agreement & Completion of Sale / Disposal of Undertaking

Ref: Our Disclosure dated August 13, 2024, made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and in furtherance to our disclosure dated August 13, 2024, regarding the approval for Sale / Disposal of an Undertaking, we wish to inform you that, in accordance with the approvals granted by the Board of Directors of the Company at its meeting held on August 13, 2024, and by the shareholders at the Annual General Meeting held on September 25, 2024, the Company has executed an agreement for the Sale / Disposal of its manufacturing unit located at No. 13, S.V. Koil Street, Madhavaram, Chennai – 600060 ("Transferred Undertaking") to M/s. Navron Pharma Private Limited ("the Buyer") and the transaction has been consummated on June 30, 2025.

The information required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as Annexure – I.

We request you to take the information and documents on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

Mohanachandran A
Company Secretary & Compliance Officer



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698

Disclosure as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as under:

S. No.	Particulars	Description
01	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Revenue: Amount of Revenue contributed by Madhavaram Unit as on March 31, 2025 is Rs.11,53,099/- Percentage of Revenue contributed: 0.08% Net worth: Amount of Net Worth contributed by Madhavaram Unit as on March 31, 2025 is Rs. 89,88,267/- Percentage of Net Worth contributed: 1.55%
02	Date on which the agreement for sale has been entered into;	The Agreement was executed on June 23, 2025
03	The expected date of completion of sale/disposal;	June 30, 2025.
04	Consideration received from such sale/disposal;	Rs.1,45,13,260/- (Rupees One Crore Forty Five Lakhs Thirteen Thousand Two Hundred and Sixty Only)
05	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof;	Name of the Buyer: Navron Pharma Private Limited Regd. Office Address: No.375, Bharathiar Street, Madhavaram, Chennai – 600060 The Buyer is not related to Promoter / Promoter Group / Group Companies
06	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No, the transaction is not a related party transaction.
07	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Yes, the sale is outside of a scheme of arrangement. However, the proposed transaction does not constitute the sale of an "Undertaking", within the meaning of clause (a) of subsection (1) of Section 180 of the Companies Act, 2013. Therefore, Regulation 37A of the LODR Regulations is not applicable.
08	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not applicable as the transaction is not a slump sale.